Previous network meta-analyses have primarily focused on the overall HER2 + BC population, with limited exploration of the HR+/HER2 + subgroup.16,27–30, While a few studies have evaluated pCR rates across regimens for HR+/HER2 + BC, these analyses often lacked comprehensive consideration of long-term outcomes16,30,31. Here, ERBB2 is linked to breast cancer.